Growth and mortality outcomes for different antiretroviral therapy initiation criteria in children ages 1-5 years: A causal modeling analysis

Epidemiology

Volumn 27, Issue 2, 2016, Pages 237-246

  Schomaker, Michael ^a   Davies, Mary Ann ^a   Malateste, Karen ^b   Renner, Lorna ^c   Sawry, Shobna ^d   N'Gbeche, Sylvie ^e   Technau, Karl Günter ^f   Eboua, François ^g   Tanser, Frank ^h   Sygnaté Sy, Haby ⁱ   Phiri, Sam ^j,k   Amorissani Folquet, Madeleine ^l   Cox, Vivian ^m,n   Koueta, Fla ^o   Chimbete, Cleophas ^p   Lawson Evi, Annette ^q   Giddy, Janet ^r   Amani Bosse, Clarisse ^s   Wood, Robin ^a,t   Egger, Matthias ^a,u   Leroy, Valeriane ^b   more..

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c UNIVERSITY OF GHANA   (Ghana)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e Centre de Prise en Charge de Recherche et de Formation Enfants   (United States)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g Yopougon University Hospital   (United States)

^h UNIVERSITY OF KWAZULU NATAL   (South Africa)

ⁱ Albert Royer Hospital   (Senegal)

^j KAMUZU CENTRAL HOSPITAL   (Malawi)

^k UNIVERSITY OF NORTH CAROLINA   (United States)

^l University Hospitals   (United States)

^m MÉDECINS SANS FRONTIÈRES   (Switzerland)

ⁿ Khayelitsha ART Programme   (South Africa)

^o Charles De Gaulle Pediatric University Teaching Hospital   (Burkina Faso)

^p Newlands Clinic   (Zimbabwe)

^q Tokoin Teaching Hospital   (Togo)

^r MCCORD HOSPITAL   (South Africa)

^s MTCT Plus Programme   (Côte d’Ivoire)

^t Institute of Infectious Disease and Molecular Medicine   (South Africa)

^u UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AFRICA; AGE; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; BODY HEIGHT; BODY WEIGHT; CAUSAL MODELING; CD4 LYMPHOCYTE COUNT; CHILD; CHILD GROWTH; CHILDHOOD MORTALITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; BURKINA FASO; CAUSALITY; CHILD DEVELOPMENT; COHORT ANALYSIS; COTE D'IVOIRE; EARLY INTERVENTION; FACTUAL DATABASE; GHANA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; INFANT; MALAWI; MORTALITY; PROCEDURES; SENEGAL; SOUTH AFRICA; TIME FACTOR; TOGO; ZIMBABWE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BURKINA FASO; CAUSALITY; CD4 LYMPHOCYTE COUNT; CHILD DEVELOPMENT; CHILD, PRESCHOOL; COHORT STUDIES; COTE D'IVOIRE; DATABASES, FACTUAL; EARLY MEDICAL INTERVENTION; FEMALE; GHANA; HIV INFECTIONS; HUMANS; INFANT; MALAWI; MALE; SENEGAL; SOUTH AFRICA; TIME FACTORS; TOGO; ZIMBABWE;

EID: 84957432428     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0000000000000412     Document Type: Article

References (33)

1. UNAIDS. Report on the global AIDS epidemic 2013. geneva: UnaiDS; 2013.
2. Prendergast AJ, Penazzato M, Cotton M, et al. treatment of young children with HiV infection: using evidence to inform policymakers. PLoS Med. 2012;9:e1001273.
3. Puthanakit T, Bunupuradah T. early versus deferred antiretroviral therapy in children in low-income and middle-income countries. Curr Opin HIV AIDS. 2010;5:12-17.
4. Siegfried N, Davies MA, Penazzato M, Muhe LM, Egger M. Optimal time for initiating antiretroviral therapy (art) in HiV-infected, treatment-naive children aged 2 to 5 years old. Cochrane Database Syst Rev. 2013;10:cD010309.
5. Turkova A, Webb RH, Lyall H. When to start, what to start and other treatment controversies in pediatric HiV infection. Paediatr Drugs. 2012;14:361-376.
6. Schomaker M. implications of causal modelling studies on the question of when to start antiretroviral treatment in young children. SACEMA Quarterly. 2014. available at: http://sacemaquarterly.com/hiv-treatment/ implications-causal-modelling-studies-question-start-antiretroviral-treat-ment-young-children.html. accessed november 13, 2015.
7. Violari A, cotton MF, Gibb DM, et al.; Cher Study team. early antiret-roviral therapy and mortality among HiV-infected infants. N Engl J Med. 2008;359:2233-2244.
8. Cross Continents Collaboration For Kids (3cs4kids) analysis and Writing committee. Markers for predicting mortality in untreated HiV-infected children in resource-limited settings: a meta-analysis. AIDS. 2008;22:97-105.
9. Dunn D; HiV Paediatric Prognostic Markers collaborative Study group. Short-term risk of disease progression in HiV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet. 2003;362:1605-1611.
10. Patel K, Hernán MA, Williams PL, et al.; Pediatric Aids clinical trials group 219/219c Study team. long-term effects of highly active antiret-roviral therapy on cD4+ cell evolution among children and adolescents infected with HiV: 5 years and counting. Clin Infect Dis. 2008;46:1751-1760.
11. Welch SB, Gibb D. When should children with HiV infection be started on antiretroviral therapy? PLoS Med. 2008;5:e73.
12. Puthanakit T, Ananworanich J, Vonthanak S, et al.; Predict Study group. cognitive function and neurodevelopmental outcomes in HiV-infected children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PreDict neurodevelopmental study. Pediatr Infect Dis J. 2013;32:501-508.
13. Puthanakit T, Saphonn V, Ananworanich J, et al.; Predict Study group. early versus deferred antiretroviral therapy for children older than 1 year infected with HiV (PreDict): a multicentre, randomised, open-label trial. Lancet Infect Dis. 2012;12:933-941.
14. Schomaker M, Egger M, Ndirangu J, et al.; international epidemiologic Databases to evaluate aiDS-Southern africa (ieDea-Sa) collaboration. When to start antiretroviral therapy in children aged 2-5 years: a collab-orative causal modelling analysis of cohort studies from southern africa. PLoS Med. 2013;10:e1001555.
15. Daniel RM, Cousens SN, De Stavola BL, Kenward MG, Sterne JA. Methods for dealing with time-dependent confounding. Stat Med. 2013;32:1584-1618.
16. Daniel RM, De Stavola BL, Cousens SN. G- formula: estimating causal effects in the presence of time-varying confounding or mediation using the g-computation formula. Stata J. 2011;11:479-517.
17. Robins J, Hernan MA, Siebert U. comparative quantication of health risks: global and regional burden of disease attributable to selected major risk factors. in: ezzati M, Murray c, lopez a, eds. Effects of Multiple Interventions. geneva, Switzerland: World Health Organization; 2004:2191-2230.
18. Egger M, Ekouevi DK, Williams C, et al. cohort Profle: the international epidemiological databases to evaluate aiDS (ieDea) in sub-Saharan africa. Int J Epidemiol. 2012;41:1256-1264.
19. Fenner L, Brinkhof MW, Keiser O, et al.; international epidemiologic Databases to evaluate aiDS in Southern africa. early mortality and loss to follow-up in HiV-infected children starting antiretroviral therapy in Southern africa. J Acquir Immune Defc Syndr. 2010;54:524-532.
20. Ekouevi DK, Azondekon A, Dicko F, et al.; Iedea pediatric West africa Working group pWaDa. 12-month mortality and loss-to-program in antiretroviral-treated children: the ieDea pediatric West african Database to evaluate aiDS (pWaDa), 2000-2008. BMC Public Health. 2011;11:519.
21. Group IPW. a survey of paediatric HiV programmatic and clinical management practices in asia and sub-Saharan africa-the international epidemiologic databases to evaluate aiDS (ieDea). J Int AIDS Soc. 2013;16:17998.
22. WHO. The WHO Child Growth Standards. 2006. available at: http:// www.who.int/childgrowth/en/. accessed november 23, 2008.
23. Honaker J, King G. What to do about missing values in time-series cross-section data? Am J Polit Sci. 2010;54:561-581.
24. Westreich D, Cole SR, Young JG, et al. the parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident Aids or death. Stat Med. 2012;31:2000-2009.
25. Young JG, Cain LE, Robins JM, O'reilly EJ, Hernán M.A. comparative effectiveness of dynamic treatment regimes: an application of the parametric g-formula. Stat Biosci. 2011;3:119-143.
26. Putter H, Fiocco M, Geskus RB. tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26:2389-2430.
27. Kiragga AN, Castelnuovo B, Musomba R, et al. comparison of methods for correction of mortality estimates for loss to follow-up after art initiation: a case of the infectious Diseases institute, Uganda. PLoS One. 2013;8:e83524.
28. Schomaker M, Gsponer T, Estill J, Fox M, Boulle A. non-ignorable loss to follow-up: correcting mortality estimates based on additional outcome ascertainment. Stat Med. 2014;33:129-142.
29. Brinkhof MW, Pujades-rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One. 2009;4:e5790.
30. Bwirire LD, Fitzgerald M, Zachariah R, et al. reasons for loss to follow-up among mothers registered in a prevention-of-mother-to-child transmission program in rural Malawi. Trans R Soc Trop Med Hyg. 2008;102:1195-1200.
31. Violari A, Lindsey JC, Hughes MD, et al. nevirapine versus rito-navir-boosted lopinavir for HiV-infected children. N Engl J Med. 2012;366:2380-2389.
32. Jesson J, Koumakpai A, Dior H, Amorissani-Folquet M, Kouéta F, Aka A. effect of age at antiretroviral treatment initiation on growth catch up within the frst 24 months of treatment among HiV-infected children in the ieDea West african paediatric cohort. Pediatr Infect Dis J. 2015;34:e159-e168.
33. WHO. World Malaria Report. geneva, Switzerland: World Health Organization; 2011.